e-learning
resources
Berlin 2001
Tuesday 25.09.2001
Pulmonary hypertension (miscellanea)
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
A possible role of plasma serotonin (5-HT) and histamin level in pulmonary hypertension (PH) in patients with interstitial lung diseases (ILD)
H. E. Iartseva, V. E. Perley, V. A. Goncharova (Saint-Petersburg, Russia)
Source:
Annual Congress 2001 - Pulmonary hypertension (miscellanea)
Session:
Pulmonary hypertension (miscellanea)
Session type:
Thematic Poster Session
Number:
2815
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
H. E. Iartseva, V. E. Perley, V. A. Goncharova (Saint-Petersburg, Russia). A possible role of plasma serotonin (5-HT) and histamin level in pulmonary hypertension (PH) in patients with interstitial lung diseases (ILD). Eur Respir J 2001; 16: Suppl. 31, 2815
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Pulmonary sarcoidosis
Definition and history of sarcoidosis
The definition of pulmonary hypertension: history, practical implications and current controversies
Related content which might interest you:
The role of secondary pulmonary hypertension (SPH) in the limited exercise tolerance of patients with interstitial lung disease (ILD)
Source: Eur Respir J 2005; 26: Suppl. 49, 560s
Year: 2005
Bosentan treatment in pulmonary arterial hypertension (PAH) associated with interstitial lung diseases (ILDs)
Source: Eur Respir J 2006; 28: Suppl. 50, 426s
Year: 2006
Longterm treatment effects of pulmonary hypertantion (PH) in idiopathic pulmonary fibrosis (IPF) patients by endothelin receptor blockade (Bosentan)
Source: Eur Respir J 2007; 30: Suppl. 51, 120s
Year: 2007
Over expression of endothelin-1 (ET-1) in lung fibroblasts (LFb) from patients with pulmonary arterial hypertension (PAH), evidence for loss of inhibitory control
Source: International Congress 2016 – New findings in mucosal immunology
Year: 2016
Impact of borderline (BL) pulmonary hypertension (PH) in chronic lung diseases (CLD).
Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases
Year: 2020
Endothelin receptor antagonist (ETRA) bosentan (B) in patients with severe pulmonary hypertension (PH) associated with pulmonary disease
Source: Annual Congress 2010 - Pulmonary circulation II
Year: 2010
The composite physiological index strongly predicts mortality in interstitial lung disease (ILD) associated pulmonary hypertension (PH-ILD)
Source: International Congress 2017 – Imaging and lung disease PH
Year: 2017
Impact of bisphosphonate (BP) use on lung function decline and treatment response in patients (pts) with idiopathic pulmonary fibrosis (IPF)
Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis
Year: 2020
Pulmonary hypertension (PH) and features of pulmonary circulation in patient with lung sarcoidosis (LS)
Source: Eur Respir J 2006; 28: Suppl. 50, 354s
Year: 2006
Pulmonary arterial hypertension (PAH) in patients with lung sarcoidosis (LS)
Source: Annual Congress 2008 - Clinical aspects in the management of sarcoidosis
Year: 2008
Inflammatory biomarkers in patients with COPD and pulmonary hypertension (PH).
Source: International Congress 2019 – Pulmonary hypertension with lung diseases and experimental pulmonary hypertension
Year: 2019
Pulmonary rehabilitation (PR) outcomes in chronic obstructive pulmonary disease (COPD) compared with interstitial lung disease (ILD)
Source: Annual Congress 2011 - Pulmonary rehabilitation: looking at alternative approaches and alternative populations beyond COPD
Year: 2011
Comparison of pulmonary hypertension (PH) associated to chronic lung disease to other PH groups
Source: International Congress 2016 – Pulmonary hypertension in lung disease
Year: 2016
Effects of an acute exacerbation requiring hospitalisation (AE) on lung function, muscle force and serum IGF-I levels in male patients with chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2002; 20: Suppl. 38, 564s
Year: 2002
Alveolar lymphocytes (AL) apoptosis in interstitial lung diseases (ILD). Increased AL apoptosis rate in idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2009 - Pathogenesis of pulmonary fibrosis
Year: 2009
Effects of endothelin receptor antagonist (ERA) bosentan on myocardial glucose metabolism in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH)
Source: International Congress 2017 – PAH and CTEPH
Year: 2017
Increased lung apoptosis and expression of ceramide in subjects with chronic obstructive pulmonary disease (COPD)
Source: Annual Congress 2009 - COPD: basic science and clinical studies
Year: 2009
Increased expression of phosphodiesterase 4 (PDE4) A, B and D in alveolar macrophages from chronic obstructive pulmonary disease (COPD) patients
Source: Annual Congress 2011 - Macrophages and neutrophils in chronic lung disease
Year: 2011
Plasma level of total hydroperoxide (TH) as a marker of oxidative stress seems to be a useful index of disease severity in patients with idiopathic pulmonary fibrosis (IPF)
Source: Eur Respir J 2005; 26: Suppl. 49, 335s
Year: 2005
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept